UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325

EVALUATION OF THERAPY TARGETS IN RECURRENT DEPRESSIVE DISORDERS

Type of Article

In the Section

Abstract

According to the WHO, more than 350 million people suffer from depressive disorders. The etiology and pathogenesis of depressive episodes and recurrent depressive disorders have not yet been definitively established. The formation of depressive disorders is due to a combination of such factors as biological (constitutional and genetic), psychological and social. Taking into account the level of prevalence of depressive disorders, the assessment of their clinical and psychopathological features and approaches to their therapy continues.

In order to determine the targets of therapy for recurrent depressive disorders, an examination of patients with recurrent depressive disorders was conducted. In the conditions of the Department of borderline psychiatry of the "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine" SI: 175 patients with recurrent depression were examined, among them 74.85 % were women and 25.15 % were men. The average age of the examinees was 46.79 years (women — 52.25, men — 41.32). Based on the assessment of clinical and psychological manifestations of recurrent depressive disorders and psychopathological aspects, the targets of therapeutic influence are established: the severity of a depressive episode (mild, moderate, severe), the specificity of psychotraumatic experiences, parameters of anti-vitality and vitality, structural features of adaptation potential.

Pages

References

  1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). URI: http://ghdx.healthdata.org/gbdresults-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b.
  2. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990—2010: a systematic analysis for the Global Burden of Disease Study 2010 / Vos T., Flaxman A. D., Naghavi M. [et ] // Lancet. 2012, 380  (9859): 2163—2196. DOI: https://doi.org/10.1016/S0140-6736(12)61729-2.
  3. World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organization. 2017. 23 p. URI: https://apps.who.int/iris/handle/10665/254610. License: CC BY-NC-SA 3.0 IGO.
  4. World Health Organization. (2008). The global burden of disease : 2004 update. World Health Organization. URI: https://apps.who.int/iris/handle/10665/43942.
  5. Mosolov S. N., Vertogradova O. P., Panteleeva G. P. i dr. Profilakticheskaya e'ffektivnost' tianeptina pri rekurrentnoj depressii s chasty'mi obostreniyami. Zhurnal nevrologii i psixiatrii im. S. S. Korsakova. 2004; 104 (9): 32–8.
  6. Lifetime Prevalence and Age-Of-Onset Distributions of Mental Disorders in the World Health Organization’s World Mental Health Survey Initiative / Kessler R. C., Angermeyer M., Anthony J. C. [et al.] // World Psychiatry. 2007; 6 (3): 168—76. PMID: 18188442.
  7. A novel augmentation strategy for treating resistant major depression  / Shelton R.  , Tollefson G.  D., Tohen  M. [et al.] // Am J Psychiat. 2001; 158:131—34. DOI: https://doi.org/10.1176/appi.ajp.158.1.131.
  8. Altamura A. C. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions / A. C. Altamura, M. Percudani // J Clin Psychiat. 1993; 54 (8): 29—37. PMID: 8253703.
  9. Kessing L.V., Xansen M.G., Andersen P.K., Angst Dzh. Chislo e'pizodov kak prognosticheskij faktor riska razvitiya recidiva pri depressivnom i bipolyarnom rasstrojstvax: pozhiznenny'j prognoz (rasshirenny'j referat). Psixiatriya i psixofarmakoterapiya. 2008; 5.
  10. Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from American College of Physicians / Qaseem A., Snow V., Denberg T.  [et al.] // Ann Intern Med. 2008; 149 (18): 725—33.
  11. Fava C. The concept of  recovery in  major depression / Fava C. A., Ruini C., Belaise C. // Psychol Med. 2007; 48: 103—11. https://doi.org/DOI: https://doi.org/10.1017/S0033291706008981.
  12. Menza M. Residual symptoms in depression: Can treatment be symptom specific? / M. Menza, H. Marin, R. S. Opper // J Clin Psychiatry. 2003; 64: 516—23. DOI: https://doi.org/10.4088/jcp.v64n0504.
  13. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys / Evans-Lacko S., Aguilar-Gaxiola S., Al-Hamzawi [et al.] // Psychol Med. 2018; 48(9): 1560—1571. DOI: https://doi.org/10.1017/S0033291717003336.
  14. Social adjustment and self-esteem in remitted with mood disorders / Serretti A., Cavallini M. C., Macciardi F. [et al.] // Eur Psychiatry. 1999; 14: 137—42.